--- title: "United Guardian (OTCPK:UTGN) Q4 Loss And Margin Compression Challenge Bullish Narratives" type: "News" locale: "en" url: "https://longbridge.com/en/news/280713269.md" description: "United Guardian (OTCPK:UTGN) reported a mixed FY 2025, with Q4 showing a loss of $0.3 million in revenue and a net loss of $4.2 million. Trailing 12-month revenue is $42.3 million with a net income of $17.1 million, down from $49.3 million the previous year. The net profit margin decreased from 58.1% to 40.3%. Despite a five-year earnings growth rate of 24.1%, recent losses raise concerns about profitability. UTGN trades at a P/E of 10.9x, significantly below the peer average of 15.8x, indicating potential valuation opportunities but also liquidity risks." datetime: "2026-03-27T01:47:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280713269.md) - [en](https://longbridge.com/en/news/280713269.md) - [zh-HK](https://longbridge.com/zh-HK/news/280713269.md) --- # United Guardian (OTCPK:UTGN) Q4 Loss And Margin Compression Challenge Bullish Narratives United Guardian (OTCPK:UTGN) has wrapped up FY 2025 with a mixed set of numbers, as Q4 revenue came in at a slight loss of US$0.3 million and net income swung to a loss of US$4.2 million, against a backdrop where trailing 12 month revenue sits at US$42.3 million and net income at US$17.1 million. Over recent quarters the company has seen revenue move from US$16.2 million and EPS of US$2.33 in Q4 2024 to US$21.9 million and EPS of US$4.05 in Q1 2025, before settling at US$17.3 million and EPS of US$3.26 in Q3 2025. This leaves investors focused on how the compressed margins and recent loss shape the risk reward trade off in this latest update. See our full analysis for UTG. With the headline figures on the table, the next step is to see how these results line up with the most widely held narratives around UTGN's growth potential, risks and long term profitability story. Curious how numbers become stories that shape markets? Explore Community Narratives OTCPK:UTGN Revenue & Expenses Breakdown as at Mar 2026 ## 40.3% net margin versus 58.1% last year - On a trailing 12 month basis, UTGN shows a net profit margin of 40.3%, compared with 58.1% the prior year, alongside trailing net income of US$17.1 million on revenue of US$42.3 million. - Critics highlight that the recent deterioration in profitability weakens the bullish story built on a five year earnings compound growth rate of 24.1%, and the numbers back that concern to a degree: - Trailing 12 month earnings moved from a margin level of 58.1% to 40.3%, and FY 2025 also includes a Q4 net loss of US$4.2 million on slightly negative quarterly revenue of US$0.3 million. - At the same time, some investors still point to the longer term record, where the 24.1% annual earnings growth contrasts with the most recent year of negative earnings, as a reason to look at the full cycle rather than a single weak patch. ## Earnings swings from US$12.8m profit to Q4 loss - Within FY 2025, UTGN moved from Q1 net income of US$12.8 million on US$21.9 million of revenue to a Q4 net loss of US$4.2 million on slightly negative revenue of US$0.3 million, with Q2 also showing a loss of US$1.8 million on US$3.4 million of revenue. - What stands out for a bearish view is how these swings complicate the idea of a steadily compounding insurer, even against the solid multi year growth record: - Across Q1 to Q3 2025, basic EPS ranged from a loss of US$0.56 in Q2 to a gain of US$4.05 in Q1 and US$3.26 in Q3, before falling into a loss again in Q4 alongside the quarterly revenue dip into negative territory. - These intra year ups and downs sit next to trailing 12 month net income of US$17.1 million, which is well below the US$49.3 million level a year earlier, so bears point to the recent period as evidence that earnings can be lumpy even if the five year trend has been positive. ## P/E of 10.9x and shares 62.6% below DCF fair value - UTGN trades on a trailing P/E of 10.9x compared with a peer average of 15.8x, and the supplied DCF fair value of US$157.89 sits well above the current share price of US$59, implying the stock is about 62.6% below that DCF estimate. - Supporters of a bullish argument lean heavily on these valuation gaps, although the same dataset flags issues they need to weigh carefully: - The combination of a lower P/E than peers and the DCF fair value well ahead of the market level suggests the shares are priced more conservatively than the supplied model, yet earnings over the most recent year were negative despite that long term 24.1% growth rate. - On top of that, the shares are described as highly illiquid, so anyone attracted to the apparent discount needs to factor in trading risk alongside the margin compression from 58.1% to 40.3%. To see how other investors are joining the dots between these swings in profitability, valuation signals and liquidity risk, check out the range of community views on UTGN in the Curious how numbers become stories that shape markets? Explore Community Narratives. ## Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on UTG's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. Mixed signals on growth, profitability and valuation can feel confusing, so check the full data set for yourself and weigh both sides of the story. Then use our breakdown of 1 key reward and 2 important warning signs ## Explore Alternatives UTGN's recent year of losses, margin compression from 58.1% to 40.3%, and sharp earnings swings highlight how earnings and share liquidity risks can weigh on confidence. If that kind of lumpier earnings profile feels uncomfortable, you can quickly compare steadier candidates with the 69 resilient stocks with low risk scores and see whether they better match your risk tolerance. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) - [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md) - [UG.US](https://longbridge.com/en/quote/UG.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [Guardant Health Says US FDA Approved Liquid Biopsy Test](https://longbridge.com/en/news/287069625.md) - [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md) - [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md) - [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)